Playback speed
10 seconds
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
ACC 2024 Insights: Evolving Pharmacology for HFrEF vs. HFpFF - With or Without Chronic Kidney Disease and/or Diabetes
By
ACC 2024 Insights
FEATURING
Maria Costanzo
By
ACC 2024 Insights
FEATURING
Maria Costanzo
0 views
April 16, 2024
Chapters
Introduction & Guideline-Directed Medical Therapy
00:00
ARNI in HFrEF & HFpEF
01:33
ARNI's Renal Effects & Albuminuria
07:17
ARNI & Diabetes Management
12:43
SGLT2 Inhibitors' Broad Impact
15:09
Mechanisms of SGLT2 Inhibitors
20:48
Finerenone & Cardio-Kidney-Metabolic Syndrome
24:54
Conclusion: Therapies Across Conditions
29:23
Comments 2
Login to view comments.
Click here to Login